Valiance

Laminate Medical Technologies Ltd. is focused on enhancing vascular access for hemodialysis patients through innovative medical devices. Founded in 2012 and based in Tel Aviv, Israel, the company has developed the VasQ Device, which serves as an external support system for arteriovenous fistulas. This device is implanted during the surgical creation of the fistula and is designed to alleviate wall tension and regulate the geometry of the vein, addressing common issues such as narrowing and blockages that can occur in the first year post-surgery. By improving the patency rates of fistulas, Laminate Medical aims to significantly reduce the annual failure rate of these vascular accesses, thereby minimizing complications related to kidney failure, the need for re-interventions, and the overall healthcare costs associated with vascular access complications.

MyoScience Inc., founded in 2005 and based in Redwood City, California, focuses on the development and commercialization of innovative dermatological products. The company leverages advanced technology to create solutions aimed at addressing various skin-related issues. Through its efforts, MyoScience aims to provide effective products that enhance skin health and appearance.

FEops is a recognized pioneer in the field of physics-based simulations for minimally invasive cardiovascular devices and procedures. They apply this technology from bench to bed, by offering advice to medical device companies as well as to medical specialists and physicians. Their computer simulations have proven to provide medical device developers and manufacturers with unique insights, thereby speeding up R&D processes and supporting device safety. Physicians, for their part, benefit from new patient-specific insights that help them work more efficiently while, most importantly, improving patient safety.

NeoSync is a clinical-stage company with a proprietary platform technology being used to develop advanced, non-invasive neuromodulation products designed to treat Major Depressive Disorder and other diseases of the Central Nervous System .(Autism, Parkinson's Disease, Anxiety, Post Traumatic Stress Disorder, etc.). ​The Company is led by experienced medical device executives and entrepreneurs.

JenaValve Technology GmbH specializes in the development and manufacturing of transcatheter aortic valve implantation (TAVI) systems designed for both transapical and transfemoral implantation. Founded in 2006 and headquartered in Munich, Germany, the company offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The concept for the device was initiated by cardiologists Hans-Reiner Figulla and Markus Ferrari at the Friedrich Schiller University Clinic in Jena, Germany. Early on, JenaValve recognized the importance of safety, precision, and durability in their systems, which are crucial for effective treatment and enhancing patient well-being.

Biocartis Group NV is a molecular diagnostics company focused on enhancing clinical practice in oncology through its proprietary Idylla platform. This platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that assists in treatment selection and monitoring. Biocartis offers a range of diagnostic products, including solid biopsy tests for various mutations such as BRAF, KRAS, NRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. The company collaborates with major pharmaceutical partners like AstraZeneca and Bristol-Myers Squibb to develop companion diagnostic tests that support targeted therapies. Established in 2007 and headquartered in Mechelen, Belgium, Biocartis aims to improve the efficacy and cost-effectiveness of personalized medical treatments, contributing significantly to the fields of oncology and infectious diseases through its innovative diagnostic solutions.

MyoScience Inc., founded in 2005 and based in Redwood City, California, focuses on the development and commercialization of innovative dermatological products. The company leverages advanced technology to create solutions aimed at addressing various skin-related issues. Through its efforts, MyoScience aims to provide effective products that enhance skin health and appearance.

MDxHealth is a molecular diagnostics company focused on developing and commercializing advanced tests to assist in cancer detection and treatment. The company offers a range of products, including ConfirmMDx, a prostate cancer tissue test aimed at addressing false-negative biopsy results; SelectMDx, a non-invasive urine test for prostate cancer; and AssureMDx, a liquid biopsy test for bladder cancer that aids in cystoscopy decisions. Additionally, MDxHealth provides PredictMDx, a tissue methylation test designed to inform treatment decisions for glioblastoma. Founded in 2003 and headquartered in Herstal, Belgium, with offices in Irvine, California, and Nijmegen, the Netherlands, MDxHealth operates internationally, serving markets across Europe and the United States. The company specializes in epigenetic and molecular technologies to enhance the accuracy of cancer diagnoses and tailor personalized treatment strategies for patients.

Biocartis Group NV is a molecular diagnostics company focused on enhancing clinical practice in oncology through its proprietary Idylla platform. This platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that assists in treatment selection and monitoring. Biocartis offers a range of diagnostic products, including solid biopsy tests for various mutations such as BRAF, KRAS, NRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. The company collaborates with major pharmaceutical partners like AstraZeneca and Bristol-Myers Squibb to develop companion diagnostic tests that support targeted therapies. Established in 2007 and headquartered in Mechelen, Belgium, Biocartis aims to improve the efficacy and cost-effectiveness of personalized medical treatments, contributing significantly to the fields of oncology and infectious diseases through its innovative diagnostic solutions.